Brokerages Anticipate Silk Road Medical Inc (NASDAQ:SILK) to Post -$0.28 EPS

Brokerages expect Silk Road Medical Inc (NASDAQ:SILK) to report earnings of ($0.28) per share for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for Silk Road Medical’s earnings. The lowest EPS estimate is ($0.32) and the highest is ($0.21). Silk Road Medical reported earnings of ($0.26) per share during the same quarter last year, which would indicate a negative year over year growth rate of 7.7%. The company is scheduled to report its next earnings results on Tuesday, November 3rd.

On average, analysts expect that Silk Road Medical will report full-year earnings of ($1.12) per share for the current fiscal year, with EPS estimates ranging from ($1.26) to ($0.94). For the next year, analysts forecast that the company will post earnings of ($0.67) per share, with EPS estimates ranging from ($0.88) to ($0.29). Zacks Investment Research’s earnings per share averages are an average based on a survey of research analysts that that provide coverage for Silk Road Medical.

Silk Road Medical (NASDAQ:SILK) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.06. Silk Road Medical had a negative return on equity of 43.15% and a negative net margin of 52.69%. The business had revenue of $15.10 million during the quarter, compared to analysts’ expectations of $12.37 million. During the same quarter in the prior year, the business posted ($0.42) earnings per share. The business’s quarterly revenue was up .7% on a year-over-year basis.

Several research firms recently issued reports on SILK. SVB Leerink increased their target price on Silk Road Medical from $51.00 to $60.00 and gave the stock an “outperform” rating in a research report on Thursday, August 6th. Piper Sandler initiated coverage on Silk Road Medical in a research report on Friday, August 21st. They set a “neutral” rating and a $54.00 target price for the company. Citigroup increased their price target on Silk Road Medical from $50.00 to $58.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Zacks Investment Research raised Silk Road Medical from a “strong sell” rating to a “hold” rating in a research note on Saturday, August 1st. Finally, Stifel Nicolaus increased their price target on Silk Road Medical from $47.00 to $55.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Three analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $52.80.

NASDAQ:SILK opened at $69.61 on Thursday. The company has a current ratio of 15.50, a quick ratio of 14.50 and a debt-to-equity ratio of 0.35. Silk Road Medical has a 12-month low of $20.84 and a 12-month high of $72.19. The stock has a 50-day moving average price of $56.01 and a 200 day moving average price of $42.80. The stock has a market capitalization of $2.34 billion, a P/E ratio of -59.50 and a beta of 1.83.

In other news, CFO Lucas W. Buchanan sold 9,600 shares of the firm’s stock in a transaction that occurred on Thursday, September 17th. The stock was sold at an average price of $67.32, for a total value of $646,272.00. Also, EVP Andrew S. Davis sold 6,635 shares of the firm’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $41.95, for a total value of $278,338.25. Following the completion of the sale, the executive vice president now directly owns 25,537 shares of the company’s stock, valued at $1,071,277.15. The disclosure for this sale can be found here. Over the last three months, insiders have sold 108,837 shares of company stock valued at $5,759,843. 7.80% of the stock is owned by corporate insiders.

Several large investors have recently bought and sold shares of the company. Rathbone Brothers plc lifted its stake in shares of Silk Road Medical by 3.5% in the 2nd quarter. Rathbone Brothers plc now owns 7,750 shares of the company’s stock valued at $325,000 after purchasing an additional 260 shares during the last quarter. Mengis Capital Management Inc. lifted its stake in shares of Silk Road Medical by 2.9% in the 2nd quarter. Mengis Capital Management Inc. now owns 10,685 shares of the company’s stock valued at $447,000 after purchasing an additional 300 shares during the last quarter. Mark Sheptoff Financial Planning LLC lifted its stake in shares of Silk Road Medical by 10.0% in the 2nd quarter. Mark Sheptoff Financial Planning LLC now owns 4,400 shares of the company’s stock valued at $184,000 after purchasing an additional 400 shares during the last quarter. Royal Bank of Canada lifted its stake in shares of Silk Road Medical by 21.2% in the 1st quarter. Royal Bank of Canada now owns 3,646 shares of the company’s stock valued at $115,000 after purchasing an additional 638 shares during the last quarter. Finally, Swiss National Bank lifted its stake in shares of Silk Road Medical by 2.0% in the 1st quarter. Swiss National Bank now owns 35,900 shares of the company’s stock valued at $1,130,000 after purchasing an additional 700 shares during the last quarter.

Silk Road Medical Company Profile

Silk Road Medical, Inc operates as a medical device company in the United States. It offers ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and initiate temporary blood flow reversal; ENROUTE Transcarotid Stent System, a self-expanding, self-tapering stent with clinical data regarding lasting safety outcomes; ENHANCE Transcarotid Peripheral Access Kit for use in gaining initial access to the common carotid artery; and ENROUTE 0.014 Guidewire for navigating and crossing the target lesion for delivery of interventional devices.

Further Reading: What are gap-down stocks?

Get a free copy of the Zacks research report on Silk Road Medical (SILK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Silk Road Medical (NASDAQ:SILK)

Receive News & Ratings for Silk Road Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silk Road Medical and related companies with MarketBeat.com's FREE daily email newsletter.